Instil Bio (TIL) Competitors $21.10 +0.01 (+0.02%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TIL vs. CMPX, ADCT, RAPT, GLUE, PRTC, LXEO, ALMS, UPXI, ATXS, and KRROShould you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Compass Therapeutics (CMPX), ADC Therapeutics (ADCT), Rapt Therapeutics (RAPT), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Lexeo Therapeutics (LXEO), Alumis (ALMS), Upexi (UPXI), Astria Therapeutics (ATXS), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Instil Bio vs. Its Competitors Compass Therapeutics ADC Therapeutics Rapt Therapeutics Monte Rosa Therapeutics PureTech Health Lexeo Therapeutics Alumis Upexi Astria Therapeutics Korro Bio Instil Bio (NASDAQ:TIL) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Which has better earnings & valuation, TIL or CMPX? Compass Therapeutics has higher revenue and earnings than Instil Bio. Compass Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$74.14M-$12.92-1.63Compass Therapeutics$850K771.93-$49.38M-$0.45-10.54 Which has more risk and volatility, TIL or CMPX? Instil Bio has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Is TIL or CMPX more profitable? Compass Therapeutics' return on equity of -53.11% beat Instil Bio's return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -54.32% -33.65% Compass Therapeutics N/A -53.11%-46.14% Do institutionals & insiders believe in TIL or CMPX? 60.6% of Instil Bio shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 47.2% of Instil Bio shares are held by insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor TIL or CMPX? In the previous week, Compass Therapeutics had 7 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for Compass Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Compass Therapeutics' score of 0.93 indicating that Instil Bio is being referred to more favorably in the media. Company Overall Sentiment Instil Bio Very Positive Compass Therapeutics Positive Do analysts prefer TIL or CMPX? Instil Bio presently has a consensus target price of $88.50, indicating a potential upside of 319.33%. Compass Therapeutics has a consensus target price of $13.10, indicating a potential upside of 176.08%. Given Instil Bio's higher possible upside, research analysts clearly believe Instil Bio is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Compass Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 SummaryCompass Therapeutics beats Instil Bio on 8 of the 14 factors compared between the two stocks. Get Instil Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TIL vs. The Competition Export to ExcelMetricInstil BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.47M$3.43B$6.17B$10.57BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-1.6323.3485.8227.46Price / SalesN/A453.83579.16187.21Price / CashN/A46.7037.4661.86Price / Book0.8110.7212.696.82Net Income-$74.14M-$52.58M$3.32B$276.90M7 Day Performance1.71%1.60%1.24%0.55%1 Month Performance-8.44%17.56%11.24%7.90%1 Year Performance-48.52%17.09%75.84%40.38% Instil Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TILInstil Bio3.3224 of 5 stars$21.11+0.0%$88.50+319.3%-47.6%$142.47MN/A-1.63410Analyst ForecastCMPXCompass Therapeutics2.8011 of 5 stars$3.58-2.6%$13.10+266.4%+149.7%$493.11M$850K-7.9220ADCTADC Therapeutics2.5124 of 5 stars$4.30-3.0%$7.75+80.4%+40.2%$484.31M$70.84M-2.74310Analyst ForecastRAPTRapt Therapeutics3.3637 of 5 stars$28.59-4.3%$23.50-17.8%+86.7%$476.71MN/A-2.0380Analyst ForecastAnalyst RevisionGLUEMonte Rosa Therapeutics2.6761 of 5 stars$7.48-2.4%$15.33+105.1%+117.0%$463.39M$75.62M20.8490PRTCPureTech Health0.186 of 5 stars$18.54-2.8%N/A-11.7%$448.11M$4.83M0.00100Gap DownLXEOLexeo Therapeutics2.7993 of 5 stars$8.25+27.5%$15.33+85.9%-1.1%$447.02MN/A-2.5458Analyst ForecastGap UpHigh Trading VolumeALMSAlumis3.5694 of 5 stars$4.23+2.5%$20.17+377.3%-56.7%$444.44MN/A0.00N/APositive NewsUPXIUpexi2.4524 of 5 stars$7.51-2.4%$15.50+106.3%+132.4%$443.44M$15.81M0.00130Analyst ForecastATXSAstria Therapeutics2.0544 of 5 stars$7.63-0.7%$29.50+286.4%+3.7%$429.98MN/A-3.7930Trending NewsAnalyst DowngradeKRROKorro Bio1.6776 of 5 stars$45.67+4.5%$86.83+90.2%+29.2%$428.84M$6.28M-4.6870Analyst Forecast Related Companies and Tools Related Companies CMPX Competitors ADCT Competitors RAPT Competitors GLUE Competitors PRTC Competitors LXEO Competitors ALMS Competitors UPXI Competitors ATXS Competitors KRRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TIL) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
